Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients

Endrikat Jan; Kim So Yeon; Sakaguchi Toshiaki; Dohanish Susan; Breuer Josy

首页> 外文期刊>Acta Radiologica >Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients

【24h】

Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients

机译：加达西酯二钠的安全性：来自8194名患者的六项临床IV期研究的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Safety data on routine clinical use of gadoxetate disodium for liver magnetic resonance imaging (MRI) is not reported yet.

机译：背景尚无关于使用gadoxetate钠进行肝磁共振成像（MRI）常规临床使用的安全性数据。

著录项

来源
《Acta Radiologica》 |2016年第11期|共8页
作者
Endrikat Jan; Kim So Yeon; Sakaguchi Toshiaki; Dohanish Susan; Breuer Josy;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词
Gadoxetate disodium; liver; magnetic resonance imaging (MRI); safety;

机译：葡萄糖酸二钠;肝脏;磁共振成像（MRI）;安全性;

相似文献

外文文献
中文文献
专利

1. Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients [J] . Endrikat Jan, Kim So Yeon, Sakaguchi Toshiaki, Acta Radiologica . 2016,第11期

机译：加达西酯二钠的安全性：来自8194名患者的六项临床IV期研究的结果
2. Respiratory Motion Artifact Affecting Hepatic Arterial Phase MR Imaging with Gadoxetate Disodium Is More Common in Patients with a Prior Episode of Arterial Phase Motion Associated with Gadoxetate Disodium [J] . Bashir Mustafa R., Castelli Patricia, Davenport Matthew S., Radiology . 2015,第1期

机译：呼吸道伪影影响加多西汀二钠的肝动脉期MR成像在先天性发作期与Phase多西妥二钠相关的患者中更常见
3. Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance [J] . Endrikat Jan S., Dohanish Susan, Balzer Thomas, Journal of magnetic resonance imaging: JMRI . 2015,第3期

机译：加达西酯二钠的安全性：临床II-III期开发计划和上市后监测的结果
4. What Does Your IV Smart Pump Infusion Data Tell You about IV Clinical Practice and Patient Safety? [C] . Elizabeth STARENKYJ, Patti WOLFE, Tim HOH, International Congress on Nursing Informatics. . 2009

机译：您的IV智能泵输液数据是什么告诉您IV临床实践和患者安全性？
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients [O] . Jan Endrikat, So Yeon Kim, Toshiaki Sakaguchi, -1

机译：加达西酯二钠的安全性：来自8194位患者的六项临床IV期研究的结果
7. Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study [O] . Christoph J Zech, Carsten Schwenke, Jan Endrikat 2019

机译：糖酸酯二钠的诊断疗效和安全性与已知或疑似局灶性肝病变患者的糖酸酯二聚体：临床研究结果III研究结果

Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients

摘要

著录项

相似文献

相关主题

期刊订阅